COVID-19

Tamil Nadu To Administer 4 Lakh ‘Precaution Doses’ On Monday

New Delhi: The Tamil Nadu health department has announced that four lakh people are eligible for the booster vaccine dose on Monday.

In a statement on Sunday, the state health department also said that 10.7 lakh people can avail the booster dose in the state in January. The beneficiaries include 2.7 lakh frontline workers, 2.7 lakh healthcare workers, and five lakh people above the age of 60.

Tamil Nadu on Monday has begun ‘precaution dose’ for frontline workers and senior citizens with co-morbidities.

Tamil Nadu has 91 lakh doses of vaccine and as per the statistics and guidelines provided by the Government of India, 9.1 lakh beneficiaries will be provided with Covishield while 1.5 lakh would be administered Covaxin, the statement added.

The State Public Health Department called upon people to visit the CoWIN portal and check their eligibility for the booster dose and then approach the centres from where they had taken the first two doses of the Covid vaccine. The booster dose, according to them, is also available at all health centres under the government or any private hospital.

All the frontline workers, healthcare workers, and those above 60 and vaccinated before April 14 are eligible for the booster dose of the vaccine.

Meanwhile, state Health Secretary J Radhakrishnan asserted that the government is geared up to deal with the rising cases in the state. “We’re one of the leading States in vaccination of children in the country. As of now, the cases are on a rising trend but hospitalisations are less. We are adding 50,000 beds to the existing 1.5 lakh hospital beds in the State,” Radhakrishnan told ANI news agency.

Telangana starts administering ‘Precaution dose’

Telangana too started to administer precaution doses to the senior citizens with co-morbidities on Monday. Telangana Health Minister T Harish Rao was present at the Government Unani Hospital in Hyderabad during the nurses gave Covid precaution doses to the beneficiaries.

Source

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button